Prevnar 13 Vaccine For Pneumococcal Disease For Adults Meets All Endpoints

Links shared publicly online about this topic.

304
total visits

Prevnar 13 Vaccine For Pneumococcal Disease For Adults Meets All Endpoints

Prevnar 13, a pneumonia vaccine, was found effective for patients aged 50+ in two clinical trials as its maker, Pfizer, applies to expand the vaccine's use. Pfizer says the vaccine met all study e

View full resource at medicalnewstoday.com

Tags: Vaccination, Pneumonia, Pneumococcal Disease, Pneumococcal Vaccine, Disease and Condition, Vaccine, Prevnar, disease

Most Recently Shared on May 10, 2011 at 8:05 am By:

MNT Vaccines

Prevnar 13 Vaccine For Pneumococcal Disease For Adults Meets All Endpoints http://mnt.to/3VBH #vaccines #immunesystem

11 months ago...

Retweet

Favorite

Also Shared By:

MNT Health News

MNT Infect Diseases

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

news-medical.net — “Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.” View full resource at news-medical.net